Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

106.34 -0.39 (-0.37%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
69 70 Next >
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
Via Benzinga
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck (MRK) Q1 2023 Earnings Call Transcript
MRK earnings call for the period ending March 31, 2023. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Merck Stock Is Trading Higher Today
Merck & Co Inc's (NYSE: MRK) Q1 sales reached $14.49 bi 
Via Benzinga
Here's How Much $100 Invested In Merck & Co 5 Years Ago Would Be Worth Today
Via Benzinga
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Germany's Possible Export Ban On Semiconductor Chemicals To China: What It Means For The U.S
Via Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone... 
Via Benzinga
2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back
Earnings season is approaching its peak. 
Via The Motley Fool
Merck Makes a Bold Move That Could Transform Its Business
It's a risky deal for Merck, but it could pay off significantly. 
Via The Motley Fool
Merck: Surpasses Q1 Earnings And Revenue Estimates
Merck came out with quarterly earnings of $1.40 per share. 
Via Talk Markets
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
Merck Announces First-Quarter 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
The 7 Best Stocks From Schwab’s Dividend ETF
Investors may beat the market by cherry-picking the best dividend stocks from the Schwab income exchange-traded fund. 
Via InvestorPlace
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
The major indexes saw modest declines, holding in a range. 
Via Investor's Business Daily
Why Prometheus Biosciences Stock Is Skyrocketing This Week
There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher. 
Via The Motley Fool
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK. 
Via The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
Two key tailwinds fueled a surge in the biotech's share price this week. 
Via The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
These two biopharma stocks could be poised for a major growth spurt. 
Via The Motley Fool
Is Moderna About to Face the Same Challenge as Other Biotechs?
Investors have gotten used to Moderna's rapid vaccine development. 
Via The Motley Fool
Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate
Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).  
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.